Announcement Highlights: The actual controller of Sanan Optoelectronics is placed under detention; Advanced Micro-Fabrication Equipment (AMEC) plans to invest 160 million yuan to increase its capital in Zhuhai Boya.

People’s Financial News, March 22 — [Hot Topics] Sanan Optoelectronics: The company’s actual controller is detained. Dongfang New Energy: The company’s recent operations are normal, and it is advancing major asset purchases. [Performance] Sinopec: Net profit in 2025 is expected to decrease by 36.8% year-on-year, with a proposed dividend of 0.2 yuan per share for the year. Electric Power Water Hydropower: Quick report for 2025 shows a net profit decrease of 34.07% year-on-year. New Dairy: Net profit in 2025 is expected to increase by 35.98% year-on-year, with a proposed dividend of 10 shares for every 3.8 yuan. Huacan Optoelectronics: Net loss of 438 million yuan in 2025, a reduction in losses year-on-year. [Increases and Reductions in Holdings] Xuefeng Technology: Controlling shareholder plans to increase holdings by 150 million to 300 million yuan. Jinming Precision Machinery: Shareholders plan to reduce holdings by no more than 3%. Dali Kaipu: Vice General Manager plans to reduce holdings by no more than 0.31%. Nenghui Technology: Shareholders plan to reduce holdings by a total of no more than 1.56%. Montai High-tech: Specific shareholders plan to reduce holdings by no more than 3%. Haixin Food: Controlling shareholder plans to reduce holdings by no more than 1%. Disen Co., Ltd.: One of the actual controllers plans to reduce holdings by no more than 1%. [Major Investments] Zhejiang Huaye: Plans to invest 1.094 billion yuan to build the Mu’ao Production Base Phase II project. Zhongwei Semiconductor: Plans to invest 160 million yuan to increase capital in Zhuhai Boya to acquire a 20% stake. [Refinancing] TENGYA Precision Engineering: Plans to raise no more than 120 million yuan through a private placement to fund the TENGYA Precision Engineering Vietnam Power Tools Manufacturing Project and others. [Others] Mingde Biotech: Stock trading may be subject to delisting risk warning. Baili Tianheng: The clinical trial approval notice for BL-ARC002 used for late-stage solid tumor treatment. *ST Busen: Yanfeng Digital and Aofei Data have no direct relationship and no business connection.